Skip to Content
Merck

D2850000

Dipyridamole

European Pharmacopoeia (EP) Reference Standard

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

50 MG

PLN 670.00

PLN 670.00

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C24H40N8O4
CAS Number:
58-32-2
Molecular Weight:
504.63
NACRES:
NA.24
PubChem Substance ID:
329798756
UNSPSC Code:
41116107
MDL number:
MFCD00010555

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dipyridamole, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

SMILES string

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI key

IZEKFCXSFNUWAM-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

dipyridamole

manufacturer/tradename

EDQM

mp

165-166 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... PDE10A(10846), PDE1A(5136), PDE1B(5153), PDE1C(5137), PDE2A(5138), PDE3A(5139), PDE3B(5140), PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144), PDE5A(8654), PDE6A(5145), PDE6B(5158), PDE6C(5146), PDE6D(5147), PDE6G(5148), PDE6H(5149), PDE7A(5150), PDE7B(27115), PDE8A(5151), PDE8B(8622), PDE9A(5152), SLC29A1(2030)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
1220506BP131Y0000802
Dipyridamole European Pharmacopoeia (EP) Reference Standard

D2850000

Dipyridamole

Dipyridamole United States Pharmacopeia (USP) Reference Standard

USP

1220506

Dipyridamole

Dipyridamole British Pharmacopoeia (BP) Reference Standard

BP131

Dipyridamole

Dipyridamole for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000802

Dipyridamole for peak identification

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

BP

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

dipyridamole

API family

dipyridamole

API family

dipyridamole

API family

dipyridamole

mp

165-166 °C (lit.)

mp

165-166 °C (lit.)

mp

165-166 °C (lit.)

mp

165-166 °C (lit.)

Application

Dipyridamole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

comparable product

Product No.
Description
Pricing

related product

Product No.
Description
Pricing

1220506

Dipyridamole, United States Pharmacopeia (USP) Reference Standard

1220517

Dipyridamole Related Compound A, United States Pharmacopeia (USP) Reference Standard

1220561

Dipyridamole Related Compound F, United States Pharmacopeia (USP) Reference Standard

1220528

Dipyridamole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1220539

Dipyridamole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1220540

Dipyridamole Related Compound D, United States Pharmacopeia (USP) Reference Standard

1220559

Dipyridamole Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP131

Dipyridamole, British Pharmacopoeia (BP) Reference Standard

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Natalie Crown et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 67(9), 728-733 (2010-04-23)
The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed. Randomized controlled trials have established the superiority of aspirinER dipyridamole over aspirin alone for secondary stroke prevention. One limitation of this
Christopher B Pattillo et al.
Annals of the New York Academy of Sciences, 1207, 83-88 (2010-10-20)
Chronic and intermittent ischemic vascular disorders represent a burgeoning clinical challenge. Previous studies have focused on the idea that therapeutic angiogenesis strategies could alleviate tissue ischemia; however, it is now appreciated that vascular disease is not simply limited to vascular
Wolfgang G Eisert
Advances in cardiology, 47, 78-86 (2012-08-22)
The antithrombotic activity of dipyridamole was initially discovered in an in vivo experiment about half a century ago. At that time science had not appreciated the complexity of the regulation of local thrombus formation. Inhibition of platelets has been the
E L L M De Schryver et al.
The Cochrane database of systematic reviews, (3)(3), CD001820-CD001820 (2007-07-20)
Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk reduction compared
J Greenhalgh et al.
Health technology assessment (Winchester, England), 15(31), 1-178 (2011-09-06)
Occlusive vascular events such as myocardial infarction (MI), ischaemic stroke and transient ischaemic attack (TIA) are the result of a reduction in blood flow associated with an artery becoming narrow or blocked through atherosclerosis and atherothrombosis. Peripheral arterial disease is
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service